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Abstract
Study of glycosylation reactions of base- and sugar-modified nucleosides was 
performed and some of the procedures were applied for the synthesis of 
pyrimido[4,5-b]indole nucleosides. Only 2′-deoxy-2′-fluoro-arabinonucleoside was 
successfully synthesized with nucleobase anion glycosylation. Series of 4-substituted 
derivatives of this nucleoside was prepared for biological activity testing. 
Keywords
nucleosides, heterocycles, carbohydrates, fluorinations
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Abstrakt
Byly prostudovány glykosylační reakce pyrimidoindolové báze a modifikovaných cukrů 
a tyto postupy byly použity pro syntézu pyrimido[4,5-b]indolových nukleosidů.  
Jediným úspěšně připraveným byl 2′-deoxy-2′-fluoro-arabinonukleosid, který byl 
syntetizován glykosylací pomocí aniontu báze a halogenozy. Pro testy biologické 
aktivity byla připravena série 4-substituovaných derivátů tohoto nukleosidu.
Klíčová slova










cAMP Cyclic adenosine monophosphate
CCM Czech collection of microorganisms
CCRF-CEM Human T cell lymphoblast-like cell line
CDK Cyclin-dependent kinase
cGMP Cyclic guanosine monophosphate






DLD-1 Human colon Dukes' type C colorectal adenocarcinoma cell line
DMF N,N-Dimethylformamide
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid 
EMEA European medicines evaluation agency
Equiv. Equivalents
ESI MS Electrospray ionization mass spectrometry
Et Ethyl
FDA The US food and drug administration
HCC Hepatocellular carcinoma
HCV Hepatitis C virus
HCT 116 Human colon colorectal carcinoma cell line
HeLaS3 Human cervical adenocarcinoma cell line
HepG2 Human liver hepatocellular cell line
HL-60 Human promyelocytic leukemia cells
HMBC Heteronuclear multiple bond correlation (NMR)
HMDS Hexamethyldisilazane
HR MS High resolution mass spectrometry
HSQC Heteronuclear single quantum coherence (NMR)
HSV-1 Herpes simplex virus type 1
HT-29 Human colon adenocarcinoma grade II cell line
IR Infrared spectroscopy




MRSA Methicillin-resistant Staphylococcus aureus
Ms Mesylate
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NS5B Nonstructural protein 5B
P388 Murine monocyte/macrophage cell line
RNA Ribonucleic acid
ROESY Rotating frame Overhauser effect spectroscopy
RP-HPFC Reversed-phase high performance flash chromatography
RSV Respiratory syncytial virus
RT Room temperature
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1 Introduction
1.1 Biological role of nucleosides in the nature
Nucleosides and their derivatives are very important substances that participate in 
almost all biochemical processes in the nature. These molecules consist of nucleobase, 
either purine or pyrimidine and a five-carbon sugar (ribose or deoxyribose) moiety 
attached via β-glycosidic bond.
The most important nucleobases are purine derivatives – adenine (1) and
guanine (2) or pyrimidine derivatives – cytosine (3), uracil (4) and thymine (5)
(Figure 1). Purine and pyrimidine nucleosides form basic units of nucleic acids (DNA 
and RNA) which are responsible for carrying and expression of genetic information of 
all organisms.1
1          2                 3       4      5
Figure 1. Purine and pyrimidine nucleobases 1–5.
Adenosine triphosphate (ATP) (6) is “energy-rich” macroergic compound which 
is able to accumulate, store, carry and release the energy required for most of the 
metabolic pathways. ATP is produced from adenosine diphosphate (ADP) (7) in
metabolism processes such as photosynthesis or the biological oxidation of nutrients.
Some of the nucleosides and nucleotides play an important role in the regulation of the 
activities of large number of metabolic processes where they function as intracellular 
signals. These molecules are called second messengers and some examples are cAMP
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Figure 2. Macroergic compounds 6, 7 and second messengers 8, 9.
Derivatives of adenosine such as flavin adenine dinucleotide (FAD+) (10), 
nicotinamide adenine dinucleotide (NAD+) (11) (Figure 3) and coenzyme A (12)
(Figure 4) participate in many enzymatic reactions as coenzymes.1



















































































Figure 4. Coenzyme A (12).
Some examples of other naturally occurring purine derivatives are caffeine (13), 
uric acid (14), hypoxanthine (15) and its nucleoside inosine (16), which is present in 
tRNA and needed for codon-anticodon wooble base pairing3 and 7-methylguanosine
(17), modified nucleoside that occurs in variable loop of tRNA (Figure 5).1
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1.2 Synthetic derivatives of nucleosides
Modified nucleosides and nucleobases were one of the first chemotherapeutic agents 
used for the medical treatment of cancer.4 This group of compounds includes a variety 
of purine and pyrimidine nucleoside derivatives which are active in both solid tumours 
and malignant disorders of the blood. These nucleoside analogues behave as 
antimetabolites, compete with natural nucleosides and induce cytotoxicity through 
interaction with a large number of intracellular targets. Many series of base-modified 
nucleosides and sugar-modified nucleosides have been synthesized and tested for 
biological activity against RNA viruses including HCV, Polio and Dengue 
virus.5,6,7,8,9,10,11
1.2.1 Base-modified nucleosides
Purine nucleoside analogues have been known  for a long time as antimetabolites which 
are effectively used in the treatment of various types of cancer.12 Mechanism of action 
of these compounds starts with their transport into cells and conversion to analogues of 
cellular nucleotides catalyzed by purine metabolic pathway enzymes.13 First step of 
activation is usually monophosphorylation catalyzed by nucleoside kinases.14,15
Phosphorylated metabolites then interfere with enzymes of DNA replication and thus 
block DNA synthesis which results in damage of DNA chain and causes apoptosis of 
the cell. Some of FDA approved purine antimetabolites are cladribine (18), fludarabine
which is administered as soluble monophosphate – fludara (19) and nelarabine (20)
(Figure 6).12
    
                     
Figure 6. Purine antimetabolites 18–20.
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Cladribine (18) is used mainly for treatment of hairy-cell leukemia,4
non-Hodgkin lymphoma4 and chronic lymphocytic leukemia.16 Fludarabine (19) treats 
chronic lymphocytic leukemia16 and nelarabine (20) is used for the treatment of T cell 
malignancies.17
Other two interesting classes of nucleosides with potent cytotoxic effect against 
cancer cell lines were developed in our group. 6-hetaryl-7-deazapurine ribonucleosides
2211 and 7-hetaryl-7-deazaadenosines 2318 are derivatives of tubericidin (21). The 
highest potential in these studies showed 7-H or 7-F derivatives of 6-furyl- or 6-thienyl-
7-deazapurines 22 exerting nanomolar in vitro cytostatic activities against a wide panel 
of leukemia or cancer cell lines (Figure 7).11
       21    22      23
Figure 7. Tubericidin (21) and derived ribonucleosides 22, 23.
Derivatives of 7-hetaryl-7-deazaadenosine series 23 bearing 5-membered 
heterocycles at position 7 showed promising in vitro antiproliferative effects towards 
broad range of hematological or solid tumor cell lines and cytostatic effects comparable 
to clofarabine (45) (Figure 13, page 17). Both of these classes of nucleosides also 
showed high but non-specific anti-HCV activities.11,18
An interesting group of nucleobases are pyrimidoindoles 24–26, which are 
benzo-fused analogues of 7-deazapurines and some of these compounds were reported 
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Figure 8. Some examples of pyrimidoindoles 24–26.
Synthesis of three halogenated pyrimidoindole bases 27–29 and corresponding 
ribonucleosides was reported.7,8 Compounds 30–32 exerted interesting anti-Dengue 
virus or anti-HCV activities, but in some cases accompanied by cytotoxicity (Figure 9).
Compared to 6-hetaryl-7-deazapurine 22 and 7-hetaryl-7-deazaadenosine
ribonucleosides 23 (Figure 7) more specific anti-HCV activity but no significant 
activity against leukemia or cancer cell lines was observed for pyrimidoindole 
ribonucleosides 30–32.
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27 R1 = H; R2 = H
28 R1 = Cl; R2 = H
























HCV infection is the most common infection causing liver disease worldwide with 
more than 180 million people infected.21 This infection is caused by blood-borne RNA 
virus from the flavivirus family22 and it can cause both acute and chronic hepatitis 
infection. Chronic infection can lead to cirrhosis of the liver and HCC.23 Several 
modified purine nucleosides, such as 2′-β-C-methyl ribonucleosides were found to show 
significant anti-HCV activity.24 Eldrup et al. reported synthesis and SAR of purine 
ribonucleosides as inhibitors of HCV RNA replication.25 2′-β-C-Methyladenosine (33)
and 2′-β-C-methylguanosine (34) (Figure 10) were reported as potent and selective 
inhibitors of HCV RNA replication, and their triphosphate forms were found to be 
active in the inhibition of HCV NS5B-mediated RNA synthesis. Base modified 
analogue of (33) 2′-β-C-methyl-7-deazaadenosine (35) showed promising antiviral 
activity and in vivo pharmacokinetics were successfully tested in three animal species.26
  33      34     35
Figure 10. 2′-β-C-Methyl ribonucleosides 33–35 with anti-HCV activity.
Other examples include 2′-β-C-methyl nucleoside analogues of toyocamycin
(36) and sangivamycin (37), nucleoside antibiotics occuring in the nature. These 
derivatives (Figure 11) were synthesized in an effort to increase biological activity of 
their original compounds27 and some of the derivatives 38–43 showed excellent 
anti-HCV activities (0.5–100 µM for EC50).
28
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38 R = CONH2
39 R = CNHOCH3
40 R = CNHNHOH
Figure 11. Toyocamycin (36), sangivamycin (37) and derived nucleosides 38–43.
Noroviruses are today recognized as the leading cause of epidemics of 
gastroenteritis and cause of sporadic gastroenteritis affecting millions of people. This 
illness is common cause of hospitalization for gastroenteritis, however, it can be 
sometimes fatal, especially among young children and the elderly.29 A nucleoside 
polymerase inhibitor of HCV, 2′-β-C-methylcytidine (44) (Figure 12), was reported as 
an inhibitor of the in vitro replication of (murine) norovirus.30 It has been shown that it 
inhibits virus-induced CPE formation, viral RNA synthesis and infectious progeny 
formation with EC50 values of ~2 µM.
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Other class of sugar-modified nucleosides with significant cytostatic activities 
are deoxyadenosine analogues bearing fluorine atom in the 2′-arabino moiety. 
2-Chloro-9-(2-deoxy-2-fluoro-β-D-arabino-furanosyl) adenine (45) (Figure 13) 
commercially known as clofarabine was synthesized and its activity was tested against 
several leukemic cell lines including those of human origin.31 To exert its cytotoxic 
effect, clofarabine requires intracellular phosphorylation by DCK32 and its triphosphate 
form 46 is an inhibitor of both DNA polymerase α (pol α) and ribonucleotide 
reductase.33,34  Clofarabine (45) showed potent antiproliferative activity against four 
human colon tumor cell lines (HCT116, HT-29, DLD-1, WiDr), with IC50 values of 
0.26 µM during 72 hrs exposure.31 Furthermore, it exhibited in vivo antitumor activity 
against following murine tumors: P388 leukemia, colon 36 and mammary 16/c.35 It also 
cured both early- and advanced-stage colon 36. In other study, 25% of pediatric patients 



















Figure 13. Clofarabine (45) and its triphosphate form 46.
Inserting two fluorine atoms into the deoxyribose ring of deoxycytidine led to 
synthesis of gemcitabine (47) (2′,2′-difluorodeoxycytidine) (Figure 14).37 This prodrug 
is inactive in its original form and gains biological activity by intracellular 
phosphorylation.38 There are few reasons for the significant activity of gemcitabine
(47): it is actively transported into cells through cell membrane, its phosphorylation is 
more efficient and elimination at a slower rate. Gemcitabine’s cytotoxic activity against 
cancer cells is achieved by incorporation into growing DNA chain and disruption of 
further DNA synthesis.39 This causes the apoptosis of the cell. The potent cytotoxic 
activity of gemcitabine was revealed during studies on murine and human cell lines, 
18
solid murine tumors and human tumor xenografts.40,41 Later on, treatment of patients 
with wide variety of tumors started with approval both by the FDA and the EMEA. This 
includes non-small lung cancer,42,43 breast cancer,44 adenocarcinoma of the 
pankreas,45,46,47,48 bladder cancer and ovarian cancer.38
          47      48
Figure 14. Gemcitabine (47) and 2′,2′-difluorodeoxyguanosine (48).
Inspired  by clinical success of gemcitabine (47), cytotoxicity, metabolism, and 
mechanisms of action of 2′,2′-difluorodeoxyguanosine (48) (Figure 14) were studied in 
Chinese hamster ovary cells.49 This nucleoside 48 was found to be activated by dGuo 
kinase and showed inhibitory effects on ribonucleotide reductase and DNA synthesis.
1.3 Synthetic approach towards nucleosides
Extraordinary biological activity of naturally occurring 7-deazapurine nucleosides and 
their derivatives caused interest in design and synthesis of novel types of nucleosides. 
Many studies on synthesis of 7-deazapurine nucleosides have been done in recent years 
in order to upgrade their properties. Different types of reactions for creating glycosidic 
bond between nucleobase and sugar derivatives have been introduced and optimized. 
Among them, the most commonly used nucleoside forming reactions are 
Silyl-Hilbert-Johnson reaction and the nucleobase anion glycosylation. Other 
mentionable examples of glycosylations are the fusion reaction and the metal salt 
procedure, both suffering from low yields.
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1.3.1 The fusion reaction
The fusion reaction between nucleobase and peracylated ribose is usually performed at 
temperature around 160 °C with Lewis acid as catalyst. This reaction was used for the 
first total synthesis of toyocamycin (36) and sangivamycin (37).50 Acetylated nucleoside 
51 was prepared by heating the mixture of 4-acetamido-6-bromo-5-cyanopyrrolo-
[2,3-d]pyrimidine (49) and protected ribofuranose 50 at 175 °C in the presence of 
bis(p-nitrophenyl)phosphate (Scheme 1). This intermediate 51 was subsequently 
converted to target compounds 36, 37 with series of reactions. This procedure is not 
usually used for the synthesis of nucleosides since it requires high temperature and 
affords only low yields of desired product. 
Scheme 1. The fusion reaction.
1.3.2 The metal salt procedure
In this type of glycosylation the metal salt of nucleobase reacts with protected sugar 
halide. Treatment of 4-amino-5-cyanopyrrolo[2,3-d]-pyrimidine (52) with mercuric 
chloride in aqeous sodium hydroxide solution afforded chlormercury derivative 53
which reacted with halogenose 54 and deacetylation furnished target nucleoside 36 in 
low yield (Scheme 2).51
20
Scheme 2. Toyocamycin (36) prepared by metal salt procedure.
This procedure was also used for synthesis of 4'-thio analogues of toyocamycin
(36).52 Chloromercury salt 55 of pyrollopyrimidine 66 reacted with halogenose 56 in 
dry toluene to furnish the protected intermediate 57 in 25 % yield (Scheme 3). Toxicity 


























Scheme 3. Synthesis of 4'-thio analogue 57 of toyocamycin (36).
1.3.3 Silyl-Hilbert-Johnson reaction
Silyl-Hilbert-Johnson reaction has been known as the most common method for 
glycosylation of nucleobases. Nucleoside is formed in the reaction of silylated 
nucleobase with electrophilic sugar derivative in the presence of catalyst. Several 
different protocols are used for this procedure.
Wittenberg procedure is performed in the presence of mercuric oxide and was 
successfully used for synthesis of protected pyrrolopyrimidine ribonucleosides.53 This 
two-step procedure starts with silylation of nucleobase 58 by HMDS in the presence of 
(NH4)2SO4 and is followed by second step – reaction of 59 with bromose 60 catalyzed 
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by mixture of mercuric oxide and mercuric bromide to furnish N-1 nucleoside 61
exclusively (Scheme 4).
Scheme 4. Wittenberg procedure for N-1 nucleoside 61.
In the synthesis of 2′-β-C-methyluridine,54 SnCl4 was used as catalyst. One-pot 
reaction was performed using BSA (N,O-Bis(trimethylsilyl)acetamide) as silylation 
agent and reaction of uracil (4) with ribose 62 afforded desired protected nucleoside 63
in 57 % yield (Scheme 5).
Scheme 5. Synthesis of 2′-β-C-methyluridine (63).
Other successfully used Lewis acid catalyst is TMSOTf. Using this conditions, 
acyloxonium ion is formed as intermediate. Nucleophilic attack of nucleobase is forced 
from the opposite, β-face of the molecule according to Baker’s trans rule which leads to 
β-D-nucleoside exclusively. Various 2′-deoxy-2′,2′-difluoro-L-erythro pentofuranosyl-
purine and pyrimidine nucleosides were synthesized by two-step Silyl-Herbert-Johnson 
reaction.55 In this study silylation of uracil (4) by excess of HMDS in the presence of 























addition of TMSOTf. After 10 h reflux at 90–100 °C under argon, anomeric mixture of 
target nucleoside 65 was obtained (Scheme 6).
Scheme 6. Synthesis of 2′-deoxy-2′,2′-difluoro-L-erythro-pentofuranosyl nucleoside 65.
In the synthesis of 2′-β-C-methyl toyocamycin and sangivamycin analogues
(Figure 11), nucleobase 66 was first silylated with BSA at RT and then reacted 
with 1 equiv. of protected sugar 67 in the presence of 3 equiv. of TMSOTf
(Scheme 7).28 Nucleoside 68 was obtained in 75 % yield. This improved procedure 




























Scheme 7. Vorbrüggen reaction using BSA and TMSOTf.
Analogous protocol was used in the synthesis of pyrimidoindole 
ribonucleosides.7 After 10 min silylation of 29 with BSA at RT, TMSOTf and 
ribofuranose 69 were added (Scheme 8). After 8 h heating at 60 °C, desired nucleoside 
70 was obtained in 54 % yield.
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1.3.4 Nucleobase anion glycosylation
This procedure requires the presence of a base (NaH or KOH) which forms anion of 
nucleobase by its deprotonation. Glycosidic bond is formed by reaction of this anion 
with electrophilic sugar derivative (for example halide or mesylate).
Sodium salt procedure was used to generate anion in the presence of NaH.56
Following glycosylation of nucleobase anion of 71 with benzyl-protected ribofuranose
72 gave the mixture of α- (25 %) and β-D-anomers (25 %) of target nucleoside 73
(Figure 9).
Scheme 9. Sodium salt procedure using NaH.
Glycosylation of benzoyl-protected bromose 74 and the nucleobase anion of 75
formed by NaH in dry dioxane led to nucleoside 76 in excellent 91 % yield
(Scheme 10).53
24
Scheme 10. Sodium salt procedure using NaH and dry dioxane as solvent.
In other Vorbrüggen-type condensation, DBU is used as base.  In this modified
procedure TMSOTf is added slowly to a precooled mixture of 6-chloropurine (77), 
ribose 67 and DBU. Reaction mixture is heated to 60 °C for 4 h giving the protected 
nucleoside 78 in 83 % yield (Scheme 11).57
Scheme 11. Glycosylation of 6-chloropurine (77) using DBU and TMSOTf.
For nucleobase anion glycosylation under solid-liquid conditions powdered 
KOH and TDA-1 as catalyst are required. Reaction is usually performed in MeCN or 
toluene. When sugar halide in α-configuration is used, this reaction proceeds 
stereoselectively to give β-D-nucleosides.53
This procedure was used in the synthesis of potential HCV RNA replication 
inhibitors.9 2′-β-C-Methyl ribofuranose 79 was synthesized and converted to the 
corresponding 1-bromo sugar halide 80 which then reacted with sodium salt of 71 to 


































Scheme 12. Synthesis of 2′-β-C-methyl nucleoside 81.
Conversion of 82 to bromide 83 and anion glycosylation was also used in the 






























Scheme 13. Synthesis of 7-deazaadenine 2'-deoxy-2'-fluoroarabino nucleoside 85.
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Further, nucleobase anion glycosylation procedure was used for the synthesis of 
7-deazapurine 2′-deoxy-2′,2′-difluoro ribonucleosides 86 from difluorosugar mesylate
64.59,60 Reaction was performed on a large scale (10 g of nucleobase 84) with 1 equiv. 
of TDA-1 and 2 equiv. of KOH (Scheme 14). Reaction mixture was heated at 50 °C for 
4 days and afforded mixture of anomers 86 and 87 (α/β 1:2) in 12 % yield. 
Scheme 14. Synthesis of 7-deazapurine 2′-deoxy-2′,2′-difluoro ribonucleoside 86.
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2 Aims of the thesis
1. Study of glycosylation reactions of pyrimido[4,5-b]indoles with diverse
modified ribose derivatives such as 2-C-methyl-β-D-ribofuranose, 
2-deoxy-2-fluoro-α-D-arabinose and 2-deoxy-2,2-difluoro-D-ribofuranose.
2. In successful cases, synthesis of several base-modified nucleoside derivatives 
for biological activity testing.
28
3 Results and discussion
Interest in the synthesis of pyrimido[4,5-b]indole nucleosides  was based on the 
knowledge that some of the corresponding ribonucleosides 30–32 showed promissing 
anti-HCV and anti-Dengue activity,7,8 2′-C-methylribonucleosides analogues 33–35 of 
adenosine and 7-deazapurine are active against HCV.25,28 Clofarabine (45) with fluorine 
atom at 2′ position in the deoxyribose moiety is used in the cancer treatment12,36 and 
gemcitabine (47) (2′-2′-difluorodeoxycytidine) treats various types of malignant 
tumors.38 Therefore, to complement the SAR for this class of compounds, 
2′-C-methylribo, 2′-deoxy-2′-fluoro and 2′-deoxy-2′,2′-difluororibo sugar-modified 
analogues of pyrimido[4,5-b]indole ribonucleosides were the aim of this work.
3.1 Nucleobase synthesis
Synthesis of target nucleosides started with the construction of 4,6-di-
chloro-9H-pyrimido[4,5-b]indole (29) following published procedure for synthesis of
this heterocyclic nucleobase.7 First step was the synthesis of ethyl-2-(2-nitrophenyl)-
cyanoacetate (89) from 2,4-dichloronitrobenzene (88) and cyanoacetate according to the 
reported procedure.61 Reduction of 89 with zinc dust in acetic acid followed by 
spontaneous cyclization afforded indole derivative 90 which gave keto-base 91 after 
cyclocondensation with formamide. In the final step, compound 91 was converted to 
dichloropyrimidoindole 29 by treatment with POCl3 under reflex (Scheme 15).














55 °C, 150 min
formamide,






















Scheme 15. Synthesis of 4,6-dichloropyrimidoindole 29.
3.2 Attempts at the synthesis of 2'-deoxy-2',2'-difluororibonucleoside
The first sugar derivative tried for glycosylation with 4,6-dichloro-9H-pyrimido-
[4,5-b]indole (29) was benzoyl-protected 2-deoxy-2,2-difluoro-D-erythro-
pentofuranosyl-1-mesylate (64) (Scheme 16). 
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Scheme 16. Glycosylation of base 29 with mesylate 64. Reagents: (a) KOH (2 equiv.), 
TDA-1 (1 equiv.), MeCN; (b) BSA (1 equiv.), TMSOTf (2 equiv.), MeCN; (c) NaH
(2 equiv.), MeCN.
Three different types of reactions were applied. Nucleobase anion glycosylation 
was previously used for the synthesis of 2'-deoxy-2',2'-difluororibonucleosides,59,60 thus 
this published procedure using KOH and TDA-1 at 50 °C was followed. Under these
conditions no product was observed, only few decomposed sugar fractions and
nucleobase 29 with starting sugar material 64 was recovered. Highering temperature to 
80 °C gave the same result with no product observed. Therefore, Vorbrüggen conditions 
were tried out. Silylation of 29 by BSA for 1 h at 80 °C followed by addition of 
TMSOTf and mesylate 64 and stirring at 80 °C for 1 day and at RT for 3 more days did 
not lead to desired nucleoside 92. Again, decomposed sugar fractions were only 
observed products and unreacted nucleobase 29 and some mesylate 64 were recovered. 
Sodium salt procedure using NaH was last tried option. Mixture of nucleobase 29 and 
NaH in MeCN was stirred at 80 °C for 1 h. and mesylate 64 was added by parts. After 
1 day stirring at 80 °C no product was observed, only decomposed fractions of sugar 
and unreacted sugar 64 and nucleobase 29 were obtained. All these experiments are 
summarized in Table 1.
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Table 1. Results of glycosylation reactions of 29 with 64.
Entry Reagents Equiv. of 64 Temp. Time Yield of 92
1 (a) 3 50 °C 4 days –
2 (a) 3 80 °C 4 days –
3 (b) 3 80 °C 1 day (3 more at RT) –
4 (c) 3 80 °C 1 day (3 more at RT) –
3.3 Attempts at the synthesis of 2'-C-methylribonucleoside
The second sugar derivative used for glycosylation with 29 was 1,2,3,5-tetra-O-
benzoyl-2-C-methyl-β-D-ribofuranose (67) (Scheme 17). 
Scheme 17. Vorbrüggen reaction of pyrimidoindole 29 with 2-C-methyl ribose 67
derivative.
One pot silylation using Vorbrügen conditions was sucessfully applied in the 
synthesis of pyrimido[4,5-b]indole ribonucleosides7, 8 and therefore, this procedure was 
chosen for the synthesis of 93. Nucleobase 29 was silylated by BSA for 30 min at RT
and TMSOTf with ribofuranose 67 was added. Reaction mixture was heated to 70 °C 
and after 3 h starting sugar material 67 dissapeared but no target product 93 was 
observed. Unreacted nucleobase 29 and few fractions of decomposed sugar were 
obtained. Higher temperature (85 °C) and stirring for 1 day gave the same results. 
Silylation at 60 °C for 30 min was tried out as attempt to increase amount of silylated 
nucleobase. Addition of 67 and TMSOTf (dropwise) and stirring at 80 °C for 18 h led 
again to decomposed sugar fractions and recovered nucleobase 29. Unsuccessful
32
attempts with tried conditions are summarized in Table 2.
Table 2. Results of Vorbrüggen reactions of 29 with 67.
Entry Equiv. of 67 Temp. Time Yield of 93
1 1 70 °C 3 h –
2 2 85 °C 1 day –
3 3 80 °C 18 h –
3.4 Synthesis of 2'-deoxy-2'-fluoroarabinonucleoside
For glycosylation of nucleobase 29 with 2-fluoroarabinofuranose 82, nucleobase anion 
glycosylation using KOH and TDA-1 or Vorbrüggen conditions were applied in order 
to synthesize desired nucleoside 94 (Scheme 18).
Scheme 18. Synthesis of 2'-deoxy-2'-fluroarabinonucleoside 94. Reagents: (a) 1. HBr in 
acetic acid, DCM 2. KOH (3 equiv.), TDA-1 (1 equiv.), MeCN; (b) BSA (1 equiv.), 
TMSOTf (2 equiv.), MeCN.
Conversion to bromose followed by nucleobase anion glycosylation was used 
for the synthesis of potential HCV RNA replication inhibitors9 and 
2'-deoxy-2'-fluroarabinonucleosides.58 1-Bromo sugar 83 was prepared by treatment of 
82 with 33 % HBr in acetic acid according to literature conditions.9 Bromose 83 was 
then dissolved in anhydrous MeCN and added (dropwise) to the mixture of nucleobase 
29, KOH and TDA-1 in MeCN. After 20 h stirring at RT and work-up, desired 
nucleoside 94 was obtained in 10 % yield. Higher temperature of the reaction (50 °C), 
did not significantly increase the yield (11 %). With 2 equiv. of halogenose 83 used at 
RT yield of nucleoside 94 was increased to 30 % and with 3 equiv. of 83 51 % of 
desired product 94 was obtained. Vorbrüggen conditions were also applied. Nucleobase 
33
29 was silylated by BSA at 80 °C for 1 h, then furanose 82 with TMSOTf was added 
and reaction mixture was stirred for 1 day at 80 °C, however, only trace amount of 
product 94 was obtained. Results are summarized in Table 3. Therefore nucleobase 
anion glycosylation proved to be the best option for sugar derivative 82, however, there 
is still some space for optimalization by increasing the amount of bromose 83 or 
temperature around 30–40 °C. 
Table 3. Glycosylation of 29 with sugar derivative 82.
Entry Reagents Equiv. of 82 Temp. Time Yield of 94
1 (a) 1 RT 20 h 10 %
2 (a) 1 50 °C 20 h 11 %
3 (a) 2 RT 20 h 30 %
4 (a) 3 RT 20 h 51 %
5 (b) 1 80 °C 1 day <1 %
3.5 Synthesis of 4-substituted 2'-deoxy-2'-fluoroarabinonucleosides 
All the active compounds from the studies7,8 were bearing a substituent at position 4 of 
the pyrimidoindole system. Previous study of the regioselectivity of the Suzuki-Miyaura 
and Stille cross-coupling reactions resulted in fully selective formation of 4-substituted 
ribonucleosides. This is due to higher reactivity of the chlorine at position 4 which is 
caused by electron-poor nature of the pyrimidine part of the molecule, while benzene 
part of the molecule makes chlorine at the position 6 much less reactive. Distribution of 
the electrons makes this benzofused system also accessible for the nucleophilic 
substitution at the position 4. Despite extremely low reactivity, chlorine at position 6 
was also successfully substituted and 4,6-disubstituted pyrimidoindole ribonucleosides 
were synthesized performing second cross-coupling reaction using X-Phos ligand in 
DMF.7 However, none of the 4,6-disubstituted nucleosides showed any significant 
antiviral activity. The highest anti-viral activity potential in the 4-(het)aryl-6-chloro-
pyrimido[4,5-b]indole ribonucleoside series displayed 4-amino, 4-methyl or 
4-(furan-2-yl) substituted derivatives which were therefore, along with 4-(furan-3-yl) 
derivative, chosen for the synthesis of final nucleosides.
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Nucleoside 94 was converted to the final deprotected 4-amino derivative 95 in 
78 % yield by treatment with aqeous amonia in dioxane (Scheme 19).
Scheme 19. Amination and deprotection of 94.
Other substituents to the position 4 were introduced by cross-coupling 
reactions.62 Protected 4-methyl nucleoside 96 was synthesized by palladium-catalyzed 
cross coupling reaction of 94 with trimethylaluminium in 46 % yield. Deprotection of 
96 under Zemplén deacetylation conditions afforded final 4-methyl nucleoside 99 in
78 % yield. 2-Furyl derivative 97 was prepared by Stille cross-coupling with 
2-(tributylstannyl)furane using PdCl2(PPh3)2 as catalyst in 79 % yield. After 
deprotection, final 2-furyl nucleoside 100 was obtained in 69 % yield. 3-Furyl 
nucleoside 98 was obtained by Suzuki cross-coupling reaction of 94 with furan-3-yl 
boronic acid catalyzed by Pd(PPh3)4. Good yield (77 %) was obtained with 1 extra 
addition of boronic acid and catalyst, without full conversion of starting material. 
Deprotection of 98 aforded final 3-furyl derivative 101 (Scheme 20). In this case, 
purification using normal-phase HPFC was not successful, therefore RP-HPFC was 
aplied to obtain pure 101. These two needed purifications caused low 33 % yield.
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Scheme 20. Synthesis of final compounds 99–101. Reagents: (a) (Me)3Al (2M in 
toluene, 2 equiv.), Pd(PPh3)4 (0.05 equiv.), THF; (b) 2-(tributylstannyl)furane
(1.2 equiv.), PdCl2(PPh3)2 (0.05 equiv.), DMF; (c) furane-3-boronic acid (1.5 equiv.), 
K2CO3 (2 equiv.) and Pd(PPh3)4 (0.05 equiv.), toluene.
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4 Conclusion
Different procedures and conditions were applied for glycosylations of 
4,6-dichloropyrimido[4,5-b]indole with ribose derivatives 2-C-methyl-β-D-ribo-
furanose, 2-deoxy-2-fluoro-α-D-arabinose and 2-deoxy-2,2-difluoro-D-ribofuranose in 
order to synthesize corresponding nucleosides. All attempts to synthesize 
2′-β-C-methyl-ribonucleoside and 2′-deoxy-2′,2′-difluoro-β-D-ribonucleoside failed and
4,6-dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)pyrimido-
[4,5-b]indole was the only succesfully prepared nucleoside. Nucleobase anion 
glycosylation proved to be the best option for this synthesis yielding in 51 % of desired 
nucleoside. Series of 4-substituted derivatives of this nucleoside was prepared by 
nucleophilic substitution and Pd-catalyzed cross-coupling reactions in moderate to good 
yields (46 – 79 %). Screening of biological activities against viruses (HCV, RSV, 
HSV-1, HIV, Dengue, coxsackie B3 virus, influenza), cancer cell lines (HepG2, HL 60, 
HeLaS3, CCRF-CEM) and microbes (Enterococcus faecalis CCM 4224, 
Staphylococcus aureus CCM 3953, Escherichia coli CCM 3954, Pseudomonas 
aeruginosa CCM 3955, Staphylococcus aureus MRSA 4591, Staphylococcus 
haemolyticus A/16568, Escherichia coli C/16702, Pseudomonas aeruginosa A/16575) 




All the reagents and solvents were purchased from commercial suppliers and used as 
recieved. THF was dried and distilled from sodium/benzophenone. All glycosylation 
and cross-coupling reactions were performed under argon atmosphere.
Chromatography purifications were performed on a Biotage SP-1 apparatus with 
FLASH 25+M, FLASH 40+M for normal-phase or KP-C18-HS columns for 
reversed-phase HPFC. Merck Silica gel 60 was used for column chromatography. 
Monitoring of the reactions was performed using TLC Silica gel 60 F254 plates. 
Compounds were detected using shortwave (254 nm) UV lamp and solution of 
anisaldehyde.
NMR spectra were recorded on a 500 MHz spectrometer (1H at 500 MHz, 13C at 
125.7 MHz and 19F at 470.3 MHz), in CDCl3 or DMSO-d6. Chemical shifts were 
referenced to signal of TMS or DMSO and are given in ppm (δ-scale), coupling 
constants (J) in Hz. Complete assignment of all NMR signals was performed using a 
combination of 2D-NMR (H,H- COSY, H,C-HSQC and H,C-HMBC) experiments and 
configurations were established by two-dimensional ROESY spectra. Low- and 
high-resolution mass spectra were measured using electrospray ionization. Melting 
points were measured on a Stuart automatic melting point SMP40 and are uncorrected.
IR spectra (wavenumbers in cm-1) were recorded on a Brucker IFS 88 spectrometer. 
Optical rotations were measured at 25 °C in DMSO on a Autopol IV (Rudolps Research 





Compound 89 was prepared according to modified literature 
conditions.61 Ice-cooled solution of ethyl cyanoacetate (24.6 ml; 
204 mmol) in anhydrous THF under argon was treated with 
potassium tert-butoxide (23.3 g; 204 mmol). The suspension was 
stirred for 20 min and 2,4-dichloronitrobenzene (88) (20 g; 
104 mmol) was added. Reaction mixture was heated to 75 °C for 
1 day, then poured into water and acidified to pH~2 with 2M HCl.
This mixture was extracted with ether (3x150 ml). Combined organic layers were dried 
over sodium sulfate and solvents were evaporated. After drying under reduced pressure 
compound 89 (40.6 g) was obtained as brown oil. Crude material was used directly for 
the next step. For analysis, the oil was purified by column chromatography 
(hexane/EtOAc, 0–10 % EtOAc). 1H NMR is in agreement with literature.63
Ethyl 2-amino-5-chloro-1H-indole-3-carboxylate (90)
Compound 90 was prepared according to literature conditions7
Crude 89 (40 g) was dissolved in glacial acetic acid (350 ml) and 
zinc dust (30 g) was added by parts in 45 min. Resulting mixture 
was stirred for 2 h without external heating, filtered through a pad 
of celite and washed with 400 ml of acetic acid. Solvent was 
evaporated and residue was washed with 600 ml of water. After 
drying under reduced pressure compound 90 (26.7 g) was 
obtained as brown powder. Crude material was used directly
for the next step. For analysis, powder was purified by column chromatography 
(hexane/chloroform, 0–60 % chloroform). 1H NMR is in agreement with literature.64
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6-Chloro-3H-pyrimido[4,5-b]indol-4(9H)-one (91)
Compound 91 was prepared according to literature conditions.7
Crude 90 (26.7 g) was dissolved in formamide (120 ml) and
heated to 185 °C for 1 day. Cooled reaction mixture was filtered 
and washed with 1 l of water. After drying under reduced pressure 
compound 91 (14.33 g) was obtained as dark powder. Crude 
material was used directly for the next step. For analysis, powder 
was purified by column chromatogramy (chloroform/MeOH, 3 % 
MeOH). 1H NMR is in agreement with literature.7
4,6-Dichloro-9H-pyrimido[4,5-b]indole (29)
Compound 29 was prepared according to literature conditions7. 
Crude 91 (14.33 g) was dissolved in POCl3 (150 ml) and heated to 
120 °C for 2 days. POCl3 was evaporated under reduced pressure, 
residue was diluted with cold water and cooled with ice. Solution 
was slowly neutralized with aqeous ammonia to pH~7, filtered and 
washed with water, hydrochloric acid and again with water. After 
drying under reduced pressure compound 29 (7.7 g) was obtained
as dark powder. Crude material was used for glycosylations without purification. For
analysis, it was purified by column chromatogramy (chloroform/MeOH, 3 % MeOH). 
1H NMR is in agreement with literature.7 Overall yield of 4-step synthesis of the 
compound 91 was 31 %. 
5.3 2'-deoxy-2'-fluoro-arabinonucleosides
1-α-Bromo-3,5-di-O-benzoyl-2-deoxy-2-fluoro-D-arabinose (83)
Compound 83 was prepared according to modified literature 
conditions.9 HBr (33% in acetic acid; 30 ml) was added dropwise 
to ice-cooled solution of 1,3,5-tri-O-benzoyl-2-deoxy-2-
fluoro-α-D-arabinose (82) ( 3.9 g; mmol) in anhydrous DCM 
(80 ml). Cooling and stirring continued for 2 h. Reaction mixture 






pressure, residue was dissolved in DCM  and washed with water, saturated NaHCO3
and again with water. Organic layer was dried over MgSO4, filtered and solvent was 
evaporated. Compound 83 was obtained as light orange oil (4.24 g) and used for 
glycosylation without further purification. 1H NMR is in agreement with literature.65
4,6-Dichloro-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)pyrimido-
[4,5-b]indole (94)
Pyrimidoindole 29 (1 g; 4.2 mmol) and finely grounded 
potassium hydroxide (0.71 g; 12.6 mmol) were suspended in 
acetonitrile (70 ml) and TDA-1 (1.34 ml; 4.2 mmol) was added. 
Reaction mixture was stirred for 30 min at RT, crude bromose 83
(5.12 g) in acetonitrile (55 ml) was added dropwise. Reaction 
mixture was stirred for another 20 h at RT. Mixture was filtered 
through pad of celite and volatiles were removed under reduced 
pressure. Crude product was purified using HPFC
(hexane/EtOAc, 0–30 % EtOAc). Nucleoside 94 (1.244 mg; 
51 %) was obtained as yellowish solid.
Mp 158–163 °C, IR (ATR): ν = 1716, 1273, 1114, 1096, 1071, 1029, 709 cm-1.
1H NMR (500.0 MHz, DMSO-d6): 4.75 (ddd, 1H, J4',3' = 5.9, J4',5' = 4.3, 2.9, H-4'); 4.80 
(dd, 1H, Jgem = 12.3, J5'b,4' = 4.3, H-5'b); 4.94 (dd, 1H, Jgem = 12.3, J5'a,4' = 2.9, H-5'a); 
5.83 (ddd, 1H, JH,F = 51.1, J2',1' = 4.1, J2',3' = 1.9, H-2'); 5.99 (ddd, 1H, JH,F = 22.5, J3',4' = 
5.9, J3',2' = 1.9, H-3'); 7.13 (dd, 1H, J7,8 = 8.9, J7,5 = 2.2, H-7); 7.17 (dd, 1H, JH,F = 21.4, 
J1',2' = 4.1, H-1'); 7.57, 7.60 (2 × m, 2 × 2H, H-m-Bz); 7.72, 7.74 (2 × m, 2 × 1H, H-p-
Bz); 7.97 (ddd, 1H, J8,7 = 8.9, JH,F = 3.2, J8,5 = 0.5, H-8); 8.07, 8.12 (2 × m, 2 × 2H, H-o-
Bz); 8.26 (dd, 1H, J5,7 = 2.1, J5,8 = 0.5, H-5); 8.93 (s, 1H, H-2).
13C NMR (125.7 MHz, 
DMSO-d6): 63.16 (CH2-5'); 76.62 (d, JC,F = 28.6, CH-3'); 77.70 (d, JC,F = 2.5, CH-4'); 
83.14 (d, JC,F = 17.5, CH-1'); 95.38 (d, JC,F = 193.2, CH-2'); 111.07 (C-4a); 116.37 (d, 
JC,F = 6.0, CH-8); 119.65 (C-4b); 121.50 (CH-5); 127.26 (C-6); 128.01 (CH-7); 128.89 
(C-i-Bz); 128.99, 129.07 (CH-m-Bz); 129.45 (CH-o-Bz); 129.47 (C-i-Bz); 129.87 (CH-
o-Bz); 133.87, 134.15 (CH-p-Bz); 137.14 (C-8a); 152.51 (C-4); 154.80 (CH-2); 155.51 
(C-9a); 165.18, 165.54 (CO-Bz). 19F{1H} NMR (470.3 MHz, DMSO-d6): -189.41.
ESI MS m/z (rel.%): 602.0 (100) [M+Na]+.
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HR MS (ESI) for C29H21Cl2FN3O5 [M+H]
+: calcd 580.08357; found 580.08368.
4-Amino-6-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-pyrimido-
[4,5-b]indole (95)
Nucleoside 94 (300 mg; 0.52 mmol) was dissolved in dioxane 
(2 ml) and 30% aqeous ammonia (6 ml) was added. Mixture 
was stirred in screw-cap pressure glass tube at 100 °C for 2 
days. Volatiles were removed under reduced pressure and crude 
product was purified using HPFC (DCM/MeOH, 0–20 % 
MeOH). After recrystallization from MeOH/H2O mixture 
desired product 95 (145 mg; 78 %) was obtained as white 
crystals. 
Mp 267–272 °C; [α]D 40.1 (c 0.299).
IR (ATR): ν = 3484, 3327, 3153, 2939, 1655, 1590, 1576, 1462, 1306, 1043, 797, 
426 cm-1.
1H NMR (499.8 MHz, DMSO-d6): 3.73-3.85 (m, 3H, H-4',5'); 4.46 (dddd, 1H, JH,F = 
23.5, J3',4' = 5.5, J3',OH = 5.3, J3',2' = 2.4, H-3'); 5.14 (ddd, 1H, JH,F = 53.3, J2',1' = 4.4, J2',3' = 
2.4, H-2'); 5.17 (t, 1H, JOH,5' = 5.5, OH-5'); 5.92 (d, 1H, JOH,3' = 5.3, OH-3'); 6.84 (dd, 
1H, JH,F = 21.1, J1',2' = 4.4, H-1'); 7.35 (dd, 1H, J7,8 = 8.8, J7,5 = 2.1, H-7); 7.47 (bs, 2H, 
NH2); 7.87 (dd, 1H, J8,7 = 8.8, JH,F = 3.1, H-8); 8.33 (s, 1H, H-2); 8.46 (d, 1H, J5,7 = 2.1, 
H-5). 13C NMR (125.7 MHz, DMSO-d6): 60.33 (CH2-5'); 74.29 (d, JC,F = 24.1, CH-3'); 
82.52 (d, JC,F = 17.6, CH-1'); 82.95 (d, JC,F = 4.6, CH-4'); 94.86 (C-4a); 98.14 (d, JC,F = 
192.1, CH-2'); 115.43 (d, JC,F = 5.3, CH-8); 120.39 (CH-5); 121.77 (C-4b); 124.46 (CH-
7); 126.01 (C-6); 135.33 (C-8a); 155.38 (C-9a); 155.52 (CH-2); 157.87 (C-4). 19F{1H} 
NMR (470.3 MHz, DMSO-d6): -188.81.
ESI MS m/z (rel.%): 353.0 (85) [M+H]+, 375.0 (100) [M+Na]+.
HR MS (ESI) for C15H14ClFN4O3 [M+H]




Protected nucleoside 94 (300 mg; 0.52 mmol ) and Pd(PPh3)4
(30 mg; 0.03 mmol) were dissolved in anhydrous THF  (10 ml) 
and (Me)3Al (520 μl, 2M in toluene) was added. Reaction 
mixture was stirred at 70 °C for 18 h. Solvents were removed 
under reduced pressure and crude product was purified using 
HPFC (hexane/EtOAc, 0–40 % EtOAc). Desired product 96
(135 mg; 46 %) was obtained as yellowish solid.
Mp 139–146 °C; IR (ATR): ν = 1721, 1477, 1454, 1264, 1164, 1115, 1101, 1072, 1043, 
1031, 711 cm-1.
1H NMR (500.0 MHz, DMSO-d6): 2.96 (s, 3H, CH3); 4.71-4.73 (m, 1H, Jgem = 9.3, J5'b,4'
= 5.2, H-5'b); 4.78 (dd, 1H, Jgem = 10.6, J5'a,4' = 3.1, H-5'a); 4.94 (dd, 1H, J4',3' = 4.7, J4',5'
= 4.8, 3.3, H-4'); 5.71 (ddd, 1H, JH,F = 21.5, J3',4' = 5.7, J3',2' = 2.5, H-3'); 6.00 (ddd, 1H, 
JH,F = 51.7, J2',1' = 6.5, J2',3' = 3.5, H-2'); 7.03 (dd, 1H, JH,F = 21.5, J1',2' = 3.5, H-1'); 7.16 
(dd, 1H, J7,8 = 8.6, J7,5 = 2.2, H-7); 7.57-7.62 (m, 6H, H-m-Bz,-p-Bz); 7.91 (dd, 1H, J8,7
= 8.3, JH,F = 3.5, H-8); 8.08, 8.12 (2 × m, 2 × 2H, H-m-Bz); 8.18 (d, 1H, J5,7 = 2.7, H-5); 
8.92 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): 22.76 (CH3); 62.95 (CH2-5'); 
76.43 (d, JC,F = 28.4, CH-3'); 77.25 (d, JC,F = 16.8, CH-1'); 82.49 (d, JC,F = 2.5, CH-4'); 
94.67 (d, JC,F = 191.2, CH-2'); 111.29(C-4a); 115.61 (d, JC,F = 5.5, CH-8); 121.22 (C-
4b); 122.05 (CH-5); 126.46 (C-6); 128.01 (CH-7); 128.74 (C-i-Bz); 128.82, 128.74 
(CH-m-Bz); 128.91 (CH-o-Bz); 129.28 (C-i-Bz); 129.70 (CH-o-Bz); 133.71, 133.97 
(CH-p-Bz); 136.53 (C-8a); 154.52 (C-9a); 154.52 (CH-2); 161.13 (C-4); 165.02, 165.47 
(CO-Bz).
ESI MS m/z (rel.%): 560.0 (57) [M+H]+, 582.0 (100) [M+Na]+.
HR MS (ESI) for C30H24ClFN3O5 [M+H]




Protected nucleoside 94 (300 mg; 0.52 mmol),
2-(tributylstannyl)furane (270 mg; 0.63 mmol) and 
PdCl2(PPh3)2 (18.2 mg; 0.03 mmol) were dissolved in 
anhydrous DMF (10 ml) and heated to 100 °C for 18 h. 
Solvent was coevaporated with toluene under reduced 
pressure. Crude product was purified using column 
chromatography on silica column containing 15 % of KF. 
Column was first washed with 3 l of hexane and then gradient 
of EtOAc in hexane (20 % EtOAc) was used. Desired product 
97 (249 mg; 79 %) was obtained as yellow crystals. 
Mp 161–168 °C; IR (ATR): ν = 1723, 1439, 1266, 1252, 1090, 1071, 710 cm-1.
1H NMR (500.0 MHz, DMSO-d6): 3.89-3.91 (m, 1H, H-4'); 3.96 (dd, 1H, Jgem = 11.4, 
J5'b,4' = 6.1, H-5'b); 4.11 (dd, 1H, Jgem = 10.1, J5'a,4' = 3.2, H-5'a); 4.99 (ddd, 1H, JH,F = 
42.1, J2',1' = 3.8, J2',3' = 1.9, H-2'); 5.15 (ddd, 1H, JH,F = 23.5, J3',4' = 5.6, J3',2' = 1.3, H-3'); 
6.07 (dd, 1H, J7,8 = 7.6, J7,5 = 2.1, H-7); 6.19 (dd, 1H, J4,3 = 3.1, J4,5 = 1.6, H-4-furyl); 
6.39 (dd, 1H, JH,F = 20.2, J1',2' = 5.7, H-1'); 6.73-6.78 (m, 6H, H-m-Bz,-p-Bz); 6.79 (dd, 
1H, J7,8 = 6.9, J7,5 = 2.3, H-7); 7.11 (dd, 1H, J8,7 = 9.2, JH,F = 3.3, H-8); 7.24-7.29 (m, 
4H, H-o-Bz,8,-3-furyl); 7.52 (dd, 1H, J5,4 = 1.5, J5,3 = 0.8, H-5-furyl); 7.94 (d, 1H, J5,7 = 
2.5, H-5); 8.17 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): 62.64 (CH2-5'); 76.46 
(d, JC,F = 23.2, CH-3'); 77.38 (d, JC,F = 17.9, CH-1'); 82.65 (d, JC,F = 4.3, CH-4'); 94.68 
(d, JC,F = 188.1, CH-2'); 95.96 (C-4a); 106.76 (CH-4-furyl); 113.16 (CH-3-furyl); 
115.60 (d, JC,F = 5.2, CH-8); 120.50 (C-4b); 123.39 (CH-5); 126.47 (C-6); 127.01 (CH-
7); 128.74, 128.83 (CH-m-Bz); 128.92 (CH-o-Bz); 129.29 (C-i-Bz); 129.71 (CH-o-Bz); 
133.72, 133.98 (CH-p-Bz); 137.15 (C-8a); 147.00 (CH-5-furyl); 147.95 (C-4); 152.01 
(C-2-furyl); 154.41 (CH-2); 156.13 (C-9a); 165.02, 165.48 (CO-Bz).
ESI MS m/z (rel.%): 612.2 (70) [M+H]+, 634.2 (100) [M+Na]+.
HR MS (ESI) for C33H24ClFN3O6 [M+H]




Protected nucleoside 94 (250 mg; 0.43 mmol ), furane-3-
boronic acid (73 mg; 0.65 mmol), K2CO3 (120 mg; 0.86 mmol) 
and Pd(PPh3)4 (25 mg; 0,02 mmol) were dissolved in toluene 
(10 ml) and heated to 100 °C for 18 h. More furane-3-boronic 
acid (150 mg; 1.34 mmol) and Pd(PPh3)4 (45 mg; 0.04 mmol) 
was added and heating continued for another 2 days. Reaction 
mixture was diluted with water and extracted with chloroform.
Organic layer was washed with saturated NH4Cl and water,
then it was dried over MgSO4. Solvent was evaporated under
reduced pressure and crude product was purified using HPFC (hexane/EtOAc, 0–40 % 
EtOAc). Desired product 98 (200 mg; 77 %) was obtained as yellow crystals. 
Mp 179–187 °C; IR (ATR): ν = 1723, 1564, 1546, 1441, 1267, 1096, 1071, 803, 
711 cm-1.
1H NMR (500.0 MHz, DMSO-d6): 4.73-4.76 (m, 1H, H-4'); 4.80 (dd, 1H, , Jgem = 10.3, 
J5'b,4' = 4.7, H-5'b); 4.95 (dd, 1H, Jgem = 12.5, J5'a,4' = 2.3, H-5'a); 4.51 (ddd, 1H, JH,F = 
59.4, J2',3' = 5.3, J2',1' = 7.5, H-3'); 6.00 (ddd, 1H, JH,F = 59.4, J2',1' = 3.1, J2',3' = 3.7, H-2'); 
7.02 (dd, 1H, JH,F = 24.6, J1',2' = 4.9, H-1'); 7.13 (dd, 1H, J4,5 = 1.4, J4,2 = 1.2, H-4-furyl); 
7.23 (dd, 1H, J7,8 = 7.6, J7,5 = 3.3, H-7); 7.57-7.62 (m, 6H, H-m-Bz,-p-Bz); 7.95 (dd, 
1H, J7,8 = 7.1, J7,5 = 2.3, H-7); 8.02 (t, 1H, J8,7 = 9.9, JH,F = 4.1, H-8); 8.06-8.08 (m, 4H, 
H-o-Bz); 8.13 (dd, 2H, J5,7 = 3.0, H-5,-5-furyl); 8.56 (dd, 1H, J2,5 = 1.3, J2,4 = 0.6, H-2-
furyl); 9.05 (s, 1H, H-2). 13C NMR (125.7 MHz, DMSO-d6): 62.96 (CH2-5'); 76.45 (d, 
JC,F = 22.2, CH-3'); 77.36 (d, JC,F = 18.4, CH-1'); 82.62 (d, JC,F = 5.7, CH-4'); 94.70 (d, 
JC,F = 199.1, CH-2'); 109.90 (C-4a); 110.53 (CH-4-furyl); 115.90 (d, JC,F = 5.3, CH-8); 
120.56 (C-4b); 121.27 (CH-5); 124.05 (CH-3-furyl); 126.20 (C-6); 126.97 (CH-7); 
128.84 (CH-m-Bz); 128.92 (CH-o-Bz); 129.31 (C-i-Bz); 129.72 (CH-o-Bz); 133.72, 
133.98 (CH-p-Bz); 136.88 (C-8a); 144.53 (CH-2-furyl); 144.78 (CH-5-furyl); 153.21 
(C-4); 154.69 (CH-2); 155.41 (C-9a); 165.04, 165.49 (CO-Bz).
ESI MS m/z (rel.%): 612.0 (44) [M+H]+, 634.0 (100) [M+Na]+.
HR MS (ESI) for C33H24ClFN3O6 [M+H]
+: calcd 612.13322; found 612.13348.
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General procedure for deprotection of nucleosides
Protected nucleosides were dissolved in MeOH (10 ml) and 1M solution of MeONa in 
MeOH (1 ml) was added. Reaction mixture was stirred at RT overnight and solvent was 
evaporated under reduced pressure.
4-Methyl-6-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-pyrimido-
[4,5-b]indole (99)
Deprotection of 96 (100 mg; 0.18 mmol) according to the 
general procedure and purification by RP-HPFC on C-18 
(H2O/MeOH, 20–60 % MeOH) afforded compound 99 (49 mg; 
78 %) as white solid. 
Mp 211–216 °C; [α]D 33.0 (c 0.291).
IR (ATR): ν = 3259, 2928, 2875, 1590, 1477, 1130, 1083, 814, 
795, 590, 531 cm-1.
1H NMR (500.0 MHz, DMSO-d6): 2.95 (s, 3H, CH3); 3.78 (bdd, 1H, Jgem = 11.9, J5'b,4' = 
4.8, H-5'b); 3.83 (bdd, 1H, Jgem = 11.9, J5'a,4' = 3.4, H-5'a); 3.88 (ddd, 1H, J4',3' = 5.9, J4',5'
= 4.8, 3.4, H-4'); 4.50 (ddd, 1H, JH,F = 23.5, J3',4' = 5.9, J3',2' = 2.5, H-3'); 5.20 (bs, 1H, 
OH-5'); 5.21 (ddd, 1H, JH,F = 53.3, J2',1' = 4.5, J2',3' = 2.5, H-2'); 5.99 (bs, 1H, OH-3'); 
6.96 (dd, 1H, JH,F = 20.5, J1',2' = 4.5, H-1'); 7.55 (dd, 1H, J7,8 = 8.9, J7,5 = 2.1, H-7); 8.04 
(dd, 1H, J8,7 = 8.9, JH,F = 3.0, H-8); 8.18 (d, 1H, J5,7 = 2.1, H-5); 8.90 (s, 1H, H-2).
13C 
NMR (125.7 MHz, DMSO-d6): 22.91 (CH3); 60.23 (CH2-5'); 74.22 (d, JC,F = 24.0, 
CH-3'); 82.51 (d, JC,F = 17.6, CH-1'); 83.12 (d, JC,F = 4.8, CH-4'); 98.08 (d, JC,F = 192.1, 
CH-2'); 111.35 (C-4a); 116.31 (d, JC,F = 5.2, CH-8); 121.18 (C-4b); 121.97 (CH-5); 
126.48 (C-6); 127.10 (CH-7); 137.05 (C-8a); 154.40 (C-9a); 154.59 (CH-2); 161.03 (C-
4). 19F{1H} NMR (470.3 MHz, DMSO-d6): -188.81.
ESI MS m/z (rel.%): 352.1 (18) [M+H]+, 374.1 (100) [M+Na]+.
HR MS (ESI) for C16H16ClFN3O3 [M+H]




Deprotection of 97 (212 mg; 0.35 mmol) according to the 
general procedure and purification using HPFC (DCM/MeOH, 
0–10 %) afforded compound 100 (97 mg; 69 %) as white solid. 
Mp 75–81 °C; [α]D 41.3 (c 0.271).
IR (ATR): ν = 3181, 2918, 1470, 1446, 1073, 1054, 1040, 
1013, 793, 743 cm-1.
1H NMR (499.8 MHz, DMSO-d6): 3.77-3.92 (m, 3H, H-4',5');
4.51 (dddd, 1H, JH,F = 23.7, J3',4' = 5.8, J3',OH = 5.4, J3',2' = 2.4, H-
3'); 5.20 (t, 1H, JOH,5' = 5.4, OH-5'); 5.24 (ddd, 1H, JH,F = 53.3, J2',1' = 4.4, J2',3' = 2.4, H-
2'); 5.99 (d, 1H, JOH,3' = 5.4, OH-3'); 6.91 (dd, 1H, J4,3 = 3.5, J4,5 = 1.8, H-4-furyl); 7.03 
(dd, 1H, JH,F = 21.0, J1',2' = 4.4, H-1'); 7.60 (dd, 1H, J7,8 = 8.9, J7,5 = 2.2, H-7); 7.62 (dd, 
1H, J3,4 = 3.5, J3,5 = 0.9, H-3-furyl); 8.08 (dd, 1H, J8,7 = 8.9, JH,F = 3.2, H-8); 8.36 (dd, 
1H, J5,4 = 1.8, J5,3 = 0.9, H-5-furyl); 8.80 (d, 1H, J5,7 = 2.2, H-5); 9.00 (s, 1H, H-2).
13C 
NMR (125.7 MHz, DMSO-d6): 60.21 (CH2-5'); 74.27 (d, JC,F = 24.2, CH-3'); 82.68 (d, 
JC,F = 17.6, CH-1'); 83.23 (d, JC,F = 4.7, CH-4'); 98.13 (d, JC,F = 192.1, CH-2'); 106.88 
(C-4a); 113.32 (CH-4-furyl); 115.63 (CH-3-furyl); 116.30 (d, JC,F = 5.4, CH-8); 120.46 
(C-4b); 123.37 (CH-5); 126.54 (C-6); 127.70 (CH-7); 137.71 (C-8a); 147.07 (CH-5-
furyl); 147.98 (C-4); 152.29 (C-2-furyl); 154.50 (CH-2); 156.19 (C-9a). 19F{1H} NMR 
(470.3 MHz, DMSO-d6): -188.43.
ESI MS m/z (rel.%): 404.0 (45) [M+H]+, 425.9 (100) [M+Na]+.
HR MS (ESI) for C19H16ClFN3O4 [M+H]
+: calcd 404.08079; found 404.08078.
6-Chloro-4-(furan-3-yl)-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-pyrimido-
[4,5-b]indole (100)
Compund 98 (164 mg; 0.27 mmol) was deprotected according 
to the general procedure and purified first by HPFC 
(DCM/MeOH, 0–10 %) and then by RP-HPFC on C-18 
(H2O/MeOH, 20–60 % MeOH) affording compound 101
(37 mg; 33 %) as white solid. 
Mp 208–214 °C; [α]D 58.9 (c 0.268).
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IR (ATR): ν = 3266, 2926, 1593, 1477, 1296, 1057, 807, 602 cm-1. 
1H NMR (500.0 MHz, DMSO-d6): 3.76-3.87 (m, 2H, H-5'); 3.90 (m, 1H, H-4'); 4.51 
(m, 1H, H-3'); 5.20 (t, 1H, JOH,5' = 5.6, OH-5'); 5.24 (ddd, 1H, JH,F = 53.4, J2',1' = 4.4, J2',3' 
= 2.5, H-2'); 6.00 (d, 1H, JOH,3' = 5.2, OH-3'); 7.02 (dd, 1H, JH,F = 20.6, J1',2' = 4.4, H-1'); 
7.14 (dd, 1H, J4,5 = 1.9, J4,2 = 0.9, H-4-furyl); 7.57 (dd, 1H, J7,8 = 9.0, J7,5 = 2.1, H-7); 
8.02 (dd, 1H, J5,4 = 1.9, J5,2 = 1.5, H-5-furyl); 8.07 (dd, 1H, J8,7 = 9.0, JH,F = 3.1, H-8); 
8.08 (d, 1H, J5,7 = 2.1, H-5); 8.56 (dd, 1H, J2,5 = 1.5, J2,4 = 0.9, H-2-furyl); 9.04 (s, 1H, 
H-2). 13C NMR (125.7 MHz, DMSO-d6): 60.21 (CH2-5'); 74.23 (d, JC,F = 24.1, CH-3'); 
82.64 (d, JC,F = 17.5, CH-1'); 83.22 (d, JC,F = 4.6, CH-4'); 98.10 (d, JC,F = 192.1, CH-2'); 
109.98 (C-4a); 110.73 (CH-4-furyl); 116.57 (d, JC,F = 5.1, CH-8); 120.49 (C-4b); 
121.21 (CH-5); 124.28 (C-3-furyl); 126.23 (C-6); 127.61 (CH-7); 137.41 (C-8a); 144.60 
(CH-2-furyl); 144.89 (CH-5-furyl); 153.17 (C-4); 154.75 (CH-2); 155.44 (C-9a).
19F{1H} NMR (470.3 MHz, DMSO-d6): -188.62.
ESI MS m/z (rel.%): 404.1 (32) [M+H]+, 426.1 (100) [M+Na]+.
HR MS (ESI) for C19H16ClFN3O4 [M+H]
+: calcd 404.08089; found 404.08079.
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